Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed about submission of disclosure of related party transactions on the basis on consolidated financial statements for the half year ended September 30, 2019.
The above information is a part of company’s filings submitted to BSE.